1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Biogen To Launch Phase III Alzheimer’s Prevention Study

 
• By Eleanor Malone

The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
New Study To Test Early Use Of Aducanumab • Source: Shutterstock

Biogen Inc. will launch a new Phase III study of its anti-amyloid-beta antibody aducanumab for early use to prevent or delay the clinical onset of Alzheimer’s disease. In a fourth-quarter conference call in which executives stood firm in their policy of refusing to comment on whether (or when) they might announce details of any interim or futility analysis of the heavily watched ongoing EMERGE and ENGAGE Phase III studies of aducanumab in early Alzheimer’s, observers had to settle for hints of progress in the Alzheimer’s arena.

Biogen Revenue Details At A Glance

  • 2018 revenues $13.5bn (+10%)

Unveiling 2018 figures that showed it performed solidly if not spectacularly, Biogen said 2019 revenues would rise slightly from $13.5bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapy Areas

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.